ArticleJAMA cardiology2022
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory.
Article in JAMA cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.Nature medicine · 2026Trial
- Patient-Centered mHealth Intervention to Improve Self-Care in Patients With Chronic Heart Failure: Phase 1 Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Design, Characteristics, and Implementation of the Financial Support for Low-Income Patients with Heart Failure Trial.JACC. Advances · 2026Article
- A novel digital twin strategy to examine the implications of randomized clinical trials for real-world populations.NPJ digital medicine · 2026Article
- Access to digital health technologies: personalized framework and global perspectives.Nature reviews. Cardiology · 2026Review
- Inclusion of Participants With Non-English Language Preference in Heart Failure Clinical Trials.JACC. Heart failure · 2025Article
- Improving Representation of Underserved Populations in Cardiovascular Research.Journal of the American Heart Association · 2025Review
- Development of START-EDI guidelines for reporting equality, diversity and inclusion in research: a study protocol.BMJ open · 2025Article
- Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.Circulation. Cardiovascular quality and outcomes · 2025Article
- Advancing Health Equity in the Cardiovascular Device Life Cycle.Circulation. Cardiovascular quality and outcomes · 2025Review
- Measures to Improve Trial Enrollment: It's Game Time!JACC. Heart failure · 2024Article
- How to make cardiology clinical trials more inclusive.Nature medicine · 2024Review
- Primary care physicians and laypersons' perceptions of multicancer detection clinical trial designs.JNCI cancer spectrum · 2024Article
- Achieving Equitable Cardiovascular Care for All: ACC Board of Trustees Health Equity Task Force Action Plan.JACC. Advances · 2024Review
- Article
- More than Just a Number: Perspectives from Black Male Participants on Community-Based Interventions and Clinical Trials to Address Cardiovascular Health Disparities.International journal of environmental research and public health · 2024Article
- Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial.JACC. Advances · 2024Article
- Temporal Trends of Enrollment by Sex and Race in Major Cardiovascular Randomized Clinical Trials.CJC open · 2024Article
- Recruitment, Retention, and Participant Diversity in the Context of a Heart Failure Self-Care Digital Intervention Decentralized Clinical Trial.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Rethinking heart failure clinical trials: the heart failure collaboratory.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Importance: Despite bearing a disproportionate burden of heart failure (HF), Black and Hispanic individuals have been poorly represented in HF clinical trials. Underrepresentation in clinical trials limits the generalizability of the findings to these populations and may even introduce uncertainties and hesitancy when translating trial data to the care of people from underrepresented groups. The Heart Failure Collaboratory, a consortium of stakeholders convened to enhance HF therapeutic development, has been dedicated to improving recruitment strategies for patients from diverse and historically underrepresented groups. Observations: Despite federal policies from the US Food and Drug Administration and National Institutes of Health aimed at improving trial representation, gaps in trial enrollment proportionate to the racial and ethnic composition of the HF population have persisted. Increasing trial globalization with limited US enrollment is a major driver of these patterns. Additional barriers to representative enrollment include inequities in care access, logistical issues in participation, restrictive enrollment criteria, and English language requirements. Conclusions and Relevance: Strategies for improving diverse trial enrollment include methodical study design and site selection, diversification of research leadership and staff, broadening of eligibility criteria, community and patient engagement, and broad stakeholder commitment. In contemporary HF trials, diverse trial enrollment is not only feasible but can be efficiently achieved to improve the generalizability and translation of trial knowledge to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.